PE20221663A1 - Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano - Google Patents

Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano

Info

Publication number
PE20221663A1
PE20221663A1 PE2022001520A PE2022001520A PE20221663A1 PE 20221663 A1 PE20221663 A1 PE 20221663A1 PE 2022001520 A PE2022001520 A PE 2022001520A PE 2022001520 A PE2022001520 A PE 2022001520A PE 20221663 A1 PE20221663 A1 PE 20221663A1
Authority
PE
Peru
Prior art keywords
composition
proteoglucan
protein
binding protein
lung diseases
Prior art date
Application number
PE2022001520A
Other languages
English (en)
Inventor
Dae Kyong Kim
Yong Wei Piao
Ji Min Jang
Dan Zhou
So Yoon Yun
Bo Kyung Park
Original Assignee
Haplnscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haplnscience Inc filed Critical Haplnscience Inc
Publication of PE20221663A1 publication Critical patent/PE20221663A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AL MENOS UNO SELECCIONADO DEL GRUPO QUE CONSISTE EN PROTEINA HAPLN1 (PROTEINA 1 DE UNION DE HIALURONANO Y PROTEOGLUCANO), UN GEN QUE CODIFICA LA PROTEINA HAPLN1 Y UN AGENTE EFICAZ PARA POTENCIAR LA EXPRESION O ACTIVAR LAS FUNCIONES DE LA PROTEINA O DEL GEN HAPLN1 COMO PRINCIPIO ACTIVO; DONDE LA PROTEINA HAPLN1 COMPRENDE UNA SECUENCIA DE AMINOACIDOS QUE TIENE AL MENOS UN 95 % DE IDENTIDAD DE SECUENCIA CON SEQ ID NO: 1. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PULMONARES COMO BRONQUITIS CRONICA, ASMA, ENFISEMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA (EPOC).
PE2022001520A 2020-02-03 2021-02-02 Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano PE20221663A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200012742A KR102166453B1 (ko) 2020-02-03 2020-02-03 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
PCT/KR2021/001374 WO2021158000A1 (en) 2020-02-03 2021-02-02 Composition for preventing or treating pulmonary diseases comprising hyaluronan and proteoglycan link protein 1

Publications (1)

Publication Number Publication Date
PE20221663A1 true PE20221663A1 (es) 2022-10-26

Family

ID=72882981

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001520A PE20221663A1 (es) 2020-02-03 2021-02-02 Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano

Country Status (17)

Country Link
US (1) US12268728B2 (es)
EP (1) EP3887525B1 (es)
JP (1) JP7329877B2 (es)
KR (1) KR102166453B1 (es)
CN (1) CN115427576B (es)
AR (1) AR121243A1 (es)
AU (1) AU2021216358A1 (es)
BR (1) BR112022015361A2 (es)
CA (1) CA3166146A1 (es)
CL (1) CL2022002067A1 (es)
CO (1) CO2022011135A2 (es)
ES (1) ES2964715T3 (es)
IL (1) IL294952A (es)
MX (1) MX2022009544A (es)
PE (1) PE20221663A1 (es)
TW (1) TWI792171B (es)
WO (1) WO2021158000A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102166453B1 (ko) 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
KR102284800B1 (ko) 2020-12-30 2021-08-03 주식회사 하플사이언스 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법
KR102678583B1 (ko) * 2021-05-31 2024-06-27 중앙대학교 산학협력단 Hapln1을 포함하는 혈관질환 예방 또는 치료용 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584462Y2 (ja) 1980-10-13 1983-01-25 古賀産業株式会社 海苔「す」
KR100785969B1 (ko) 2004-05-12 2007-12-14 동아제약주식회사 Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제
CN1984650A (zh) 2004-07-16 2007-06-20 沃尼尔·朗伯有限责任公司 毛发生长促进剂
GB0422525D0 (en) 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
US20090220488A1 (en) 2005-08-31 2009-09-03 Humphrey Gardner Evaluating and treating scleroderma
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
US20080139500A1 (en) 2006-12-11 2008-06-12 Isadore Elliott Goldberg Use of composite monomer or monomers, catalyst, sodium hyaluronate or hyaluronic acid, glucosamide sulfate, chondroiten sulfate or chlorides, for the treatment of osteoarthritis by intraarticular application to a hip or knee joint
BR112012000517B1 (pt) 2009-07-10 2022-04-12 Histogen, Inc Método para produzir uma composição compreendendo uma ou mais proteínas embriônicas, composição preparada através do referido método, emplastro de regeneração ou sistema de cultura de tecido, revestimento de superfície, agente antiadesão biológico, veículo biológico, e métodos para a melhora de uma superfície da pele em um indivíduo, para gerar uma célula-tronco mul tipotente, para reparo ou aumento do tecido mole, e para promover crescimento capilar
EP2453905B1 (en) 2009-07-16 2019-12-18 Lineage Cell Therapeutics, Inc. Methods and compositions for in vitro and in vivo chondrogenesis
US20120128632A1 (en) 2009-07-23 2012-05-24 Jeffrey Keeler Teumer Identity markers
US8334136B2 (en) 2009-07-24 2012-12-18 Shiseido Company, Ltd. Method for promoting hair growth or hair regeneration by maintaining or increasing expression of cell-adhesion factor
US20130052198A1 (en) 2010-03-29 2013-02-28 The General Hospital Corporation Anti-inflammatory factors
WO2012151346A1 (en) 2011-05-03 2012-11-08 Dermachip Inc. Expression signatures of genes and gene networks associated with skin aging
EP2710373B1 (en) 2011-05-17 2015-06-17 Chanel Parfums Beauté Screening of large activators for preventing and/or attenuating skin ageing and/or hydrating skin
CN104093415B (zh) * 2011-10-24 2017-04-05 哈洛齐梅公司 抗乙酰透明质酸剂疗法的同伴诊断剂及其使用方法
JP5767591B2 (ja) 2012-01-24 2015-08-19 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 人工軟骨の製造方法
WO2013129456A1 (ja) 2012-02-29 2013-09-06 ロート製薬株式会社 線維芽細胞増殖促進能を有する組成物
WO2013144672A1 (en) 2012-03-30 2013-10-03 Société De Développement Et De Recherche Industrielle Method and kit for the classification and prognosis of wounds
WO2013165018A1 (ja) 2012-05-02 2013-11-07 三菱レイヨン株式会社 皮膚に対する紫外線の影響を評価するためのプローブ又はプローブセット及び核酸マイクロアレイ
BR112014030677A2 (pt) * 2012-06-08 2022-07-19 Shire Human Genetic Therapies distribuição pulmonar de mrna para células-alvo não-pulmonares
CN104619352B (zh) 2012-07-11 2022-02-18 组织技术公司 含有hc-ha/ptx3复合物的组合物及其使用方法
EP2716751A1 (en) 2012-10-08 2014-04-09 BioTime, Inc. Differentiated progeny of clonal progenitor cell lines
US10322125B2 (en) 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto
US20160192689A1 (en) 2013-07-31 2016-07-07 Wikifoods, Inc. Encapsulated functional food compositions
CA2923857A1 (en) 2013-09-09 2015-03-12 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
CN106456676B (zh) 2014-07-07 2021-07-23 米迪波斯特股份有限公司 经刺激的干细胞的培养基的毛发生长促进功能及其用途
JP6948945B2 (ja) 2015-01-07 2021-10-13 ファイザー・インク 骨格成長障害を治療するための可溶性ｆｇｆｒ３デコイ
GB201505520D0 (en) 2015-03-31 2015-05-13 Univ Lancaster Composition
KR101897340B1 (ko) 2015-09-09 2018-09-13 중앙대학교 산학협력단 Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물
CN108697812A (zh) 2016-01-14 2018-10-23 脊核细胞有限责任公司 用于软骨细胞或软骨类型细胞再生的细胞混合物
KR101900748B1 (ko) 2016-08-17 2018-09-20 (주)진셀팜 모발 성장 촉진 효과를 가지는 펩타이드, 및 이의 용도
EP3594685B1 (en) * 2017-03-06 2024-11-06 Haplnscience Inc. Composition for skin aging alleviation using hapln1
KR20190024727A (ko) 2017-08-29 2019-03-08 중앙대학교 산학협력단 Hapln1을 유효성분으로 함유하는 연골 재생용 조성물
WO2019045451A1 (ko) 2017-08-29 2019-03-07 중앙대학교 산학협력단 Hapln1을 유효성분으로 함유하는 연골 재생용 조성물
AR118208A1 (es) 2019-02-27 2021-09-22 Haplnscience Inc Composiciones para evitar, mejorar o tratar enfermedades o síntomas relacionados con los cartílagos, que comprenden hapln1
CN113490500A (zh) 2019-02-28 2021-10-08 哈普赛安思有限公司 包括hapln1的用于预防、改善或治疗与软骨有关的疾病或症状的组合物
CN113784723A (zh) 2019-04-30 2021-12-10 哈普赛安思有限公司 包括hapln1的用于预防或治疗脱发的组合物
KR102166453B1 (ko) 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
KR102284800B1 (ko) 2020-12-30 2021-08-03 주식회사 하플사이언스 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법

Also Published As

Publication number Publication date
CA3166146A1 (en) 2021-08-12
CL2022002067A1 (es) 2023-01-20
AR121243A1 (es) 2022-05-04
IL294952A (en) 2022-09-01
BR112022015361A2 (pt) 2022-09-20
EP3887525A1 (en) 2021-10-06
US12268728B2 (en) 2025-04-08
CO2022011135A2 (es) 2022-08-30
TWI792171B (zh) 2023-02-11
US20220305077A1 (en) 2022-09-29
ES2964715T3 (es) 2024-04-09
TW202130360A (zh) 2021-08-16
JP7329877B2 (ja) 2023-08-21
EP3887525A4 (en) 2022-06-22
WO2021158000A1 (en) 2021-08-12
KR102166453B1 (ko) 2020-10-15
EP3887525B1 (en) 2023-08-23
CN115427576A (zh) 2022-12-02
EP3887525C0 (en) 2023-08-23
JP2022524899A (ja) 2022-05-11
AU2021216358A1 (en) 2022-09-01
CN115427576B (zh) 2025-02-28
MX2022009544A (es) 2022-08-25

Similar Documents

Publication Publication Date Title
PE20221663A1 (es) Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano
AR068767A1 (es) Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
MX2021015753A (es) Constructo de arn.
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
PE20190911A1 (es) Composiciones y anticuerpos anti-lag-3
BR112021019520A2 (pt) Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica
PE20191203A1 (es) Variantes de alfa-glucosidasa acida y usos de las mismas
PE20140867A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
MX2019008949A (es) Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112022022503A2 (pt) Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
PE20180509A1 (es) Composiciones y metodos para tratar la enfermedad celiaca
BR112021024997A2 (pt) Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso
PE20230487A1 (es) Variantes de alfa-galactosidasa humana
MX2025007855A (es) Proteina triespecifica dirigida a trop2 para el tratamiento del cancer